

COMPANY PRESENTATION

Euronext STAR conference 2025

Palazzo Mezzanotte

March 26th - 27th , 2025



Member of **Euronext Tech Leaders**





Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.



- 1. Overview
- 2. Markets and Growth Drivers
- 3. Our Strategy and Market Approach
- 4. Financial Highlights
- 5. Current Outlook
- 6. Multiples & Comparables



A PRIMARY PLAYER PROVIDING MEDICAL, INDUSTRIAL AND CONSERVATION LASER SOLUTIONS WORLDWIDE



World Class Hi-Tech company

Hi-Tech industrial group providing laser solutions with proprietary technologies and know how developed over 40 years



Listed on Euronext STAR Milan of Italian Stock Exchange since year 2000 and member of Euronext Tech Leaders



Within Worldwide leaders in its space

Active worldwide on several laser application segments and markets...



...progressively widening its globalwide presence achieving continuous growth over the years

OUR APPROACH



>40

YEARS OF EXPERIENCE



>20

SUBSIDIARIES



10

COUNTRIES WITH DIRECT PRESENCE



14

PLANTS

WE CREATE LIGHT, ENERGY, WAVES



MEDICAL

Our energy based systems improve people's well-being and life quality.

In the SURGICAL SECTOR, our minimally invasive technology systems minimize pain, side effects and risks of surgical procedures and hospitalization days.

In the AESTHETIC SECTOR, our systems satisfy the growing desire of individuals to improve their appearance also reducing pathological or painful imperfections.



INDUSTRIAL

Our LASER CUTTING and MARKING SYSTEMS Improve the productivity of our customers manufacturing plants also limiting the environmental impact of manufacturing processes minimizing waste, fumes generated by the process, use of chemical additives, and allowing to eliminate the need for inks, solvents or glues within the process.



CONSERVATION

Our LASER SYSTEMS PRESERVE artworks of the universal heritage of our communities.



EthiFinance

ESG ratings

MSCI ESG RATINGS

Sustainalytics

OUR STRATEGY FOR A SUSTAINABLE FUTURE:

Create value over time and be ready to successfully meet the future challenges

R&D



8 R&D dept.



>20 MLN
Yearly R&D investments



> 370 Patents



> 240 R&D specialists

PRODUCTS



> 60.000

Laser sources installed worldwide



ISO 9001 e ISO 13485

Certifications



ISO 14064

El.En., Deka Mela and Quanta



Quality & Regulatory specialists

PEOPLE



~20% under 30 years

>2.000 employees

50% of employees have a university degree and over 90% hold either a degree or a high school diploma.



WELFARE at the heart of business projects.

Workspaces were renewed for several Group companies: employees well-being was increased and plants'energy efficiency as well



>33.000 HOURS Training

ENVIRONMENT



7 Photovoltaic systems active in 2024

2 Photovoltaic plants in progress



16%


Self-produced electrical energy share of the annual total consumption



39%

Annual electricity consumption comes from renewable sources





ELEN

Pigmented lesions



Body contouring and tightening


Antiaging/Pigmented lesions



Compact sheet metal cutting system











MINIMALLY INVASIVE SURGERIES:

- Lower risks and side effects
- Faster recovery /Shorter hospital stays
- Savings by Private & National Health Systems
- Attractive ROI for surgical services providers
- Rapidly Growing Urology laser market
- Consumables revenue stream in Urology





MEDICAL AESTHETICS MARKET TRENDS

- Aging demographics and increasing focus on improving appearance and youthfulness
- Cosmetic procedures as preventive measures for and to slow down the aging process
- Growing interest in non-invasive or minimally invasive procedures and awareness of energybased aesthetic treatments
- Reduction in procedure costs, attracting a broader patient base
- Aesthetic procedures becoming part of lifestyle and increasingly part of people's wellbeing
- Rapid growth expected







GLOBAL MEDICAL LASER MARKET

•	Mordor Intelligence	CAGR 13,4% to 2028
•	Fortune business insights	CAGR 13,1% to 2030
•	Global Market Insights	CAGR 14,5% to 2032
•	Research and Markets	CAGR 13,2% to 2030

With an estimated market size of \simeq \$5 Bln in 2021 including:

- Ophthalmology Dermatology Aesthetics- Dentistry
- Surgical -Gynecology Urology Cardiovascular

AESTHETIC LASER AND ENERGY DEVICES MARKET

•	Research and Markets	CAGR 9,45% 2023- 2028
		\$3,7Bn 2023 Market Size

Tecnavio CAGR 10,9% 2023- 2028

\$3,9Bn 2023 Market Size







Laser cutting applications:

- Laser power increase + Cost reduction: enhanced flexibility, productivity and quality standards in manufacturing processes.
- Automation for increased productivity
- New application verticals
- Building and construction







Laser marking:

- Products identification and traceability
- Minimal environmental impact

Laser processing market:

Size: \$17,48 billion in 2021

Expected CAGR to 2030: 9,1%

Source: Grand view research





Technical Knowledge



Electronics



Optics

Photonics

Mechanics



Fluid dynamics



Power electronics



Software

LASER



Application Expertise

Aesthetics



Surgery



Dermatology



Physiotherapy



Cutting




Marking



Art Conservation









- Speed
- Power
- Precision
- Selectivity
- Effectiveness









MID-TERM STRATEGIC VISION BASED ON:

- Continuous investment in R&D: maintaining the unmatched wideness of our product range by innovating existing technologies and developing new ones
- Cooperation with primary research institutions and KOL'S
- Excellent coverage of the target markets based on the widespread and loyal distribution network created over the years
- Focus on innovative products release, technical support and continuous training to our customers
- Unique Multi brand approach







WIDE RANGE OF PRODUCTS IN MEDICAL SECTOR

Hair removal









Surgery











Gynecology











TOWERMARKX







Innovative









+ gentle and

- painful







Attractive ROI for our customers





User friendly



FINANCIAL HIGHLIGHTS


Euro '000	31/12/2023	%	31/12/2024	%	Var. %
	unaudited		unaudited		
Medical	392.434	68,1%	410.401	72,5%	4,6%
Industrial	183.577	31,9%	155.444	27,5%	-15,3%
Revenues	576.011	100,0%	565.846	100,0%	-1,8%
Gross margin	234.769	40,8%	245.637	43,4%	4,6%
Operating Expenses	50.091	8,7%	55.092	9,7%	10,0%
Staff espenses	92.494	16,1%	98.770	17,5%	6,8%
EBITDA	92.184	16,0%	91.775	16,2%	-0,4%
Depr., amort., accruals	13.965	2,4%	13.467	2,4%	-3,6%
EBIT	78.219	13,6%	78.309	13,8%	0,1%
Net financ.income(charges)	(449)	-0,1%	802	0,1%	
Other income (expense) net	64	0,0%	4.993	0,9%	7642,1%
EBT	77.835	13,5%	84.104	14,9%	8,1%
Income taxes	(22.600)	-3,9%	(21.227)	-3,8%	-6,1%
Discontinued operations	(5.169)	-0,9%	(10.372)	-1,8%	100,7%
Minorities	(1.827)	-0,3%	(892)	-0,2%	-51,2%
NET INCOME	48.239	8,4%	51.613	9,1%	7,0%

The financial statements for this presentation were prepared in accordance with IAS/IFRS accounting principles, reclassifying the contribution of the Chinese industrial cutting division in the assets, liabilities and income statement results from discontinued operations, due to the ongoing negotiations for the sale of the division, in accordance with IFRS5. For a better comparison, the previous year financial statements have also been accordingly reclassified.


Euro '000	31/12/23	31/12/24	Var.%
	unaudited	unaudited	
Total non current assets	116.304	103.237	-11,2%
Net Working Capital	211.901	199.826	-5,7%
Other receivables/payables ST	(34.876)	(32.675)	-6,3%
Net financial position	59.877	110.559	84,6%
Long term liabilities	16.379	16.071	-1,9%
Net Equity	375.458	410.802	9,4%
Discontinued operation	38.630	45.926	18,9%
Net capital employed	315.581	300.243	-4,9%
Net Working Capital on sales	36,8%	35,3%	
ROCE	24,8%	26,1%	
(EBIT/Net capital employed)			
Operating Capex	11.623	13.306	

The financial statements for this presentation were prepared in accordance with IAS/IFRS accounting principles, reclassifying the contribution of the Chinese industrial cutting division in the assets, liabilities and income statement results from discontinued operations, due to the ongoing negotiations for the sale of the division, in accordance with IFRS5. For a better comparison, the previous year financial statements have also been accordingly reclassified.

***NWC= Net Working Capital









Medical: +5%

in Euro million





Industrial: -15%

2024 FINANCIALS Vs. PROFORMA W/O IFRS5

2024 Financials - Euro '	000				
P&L	31/12/2023	31/12/2023 %		%	Var.%
	unaudited		unaudited		
Revenues	576.011		565.846		-1,8%
EBIT	78.219	78.219 13,6%		13,8%	0,1%
	31/12/2023	%	31/12/2024		
	unaudited		unaudited		
NFP	59.877		110.559	_	

Financials w/o IFRS5 accounting standard

P&L	31/12/2023	%	31/12/2024	%	Var.%
	unaudited		unaudited		
Revenues	692.290		645.881		-6,7%
EBIT 72.736		10,5%	70.958	11,0%	-2,4%
				_	
	31/12/2023	%	31/12/2024	_	
	unaudited		unaudited	_	
NFP	54.586		120.364	_	
				_	



ELEN

Revenues 2025 > Revenues 2024

EBIT 2025 = EBIT 2024



MULTIPLES & COMPARABLES



Stockholder's Equity per share					
Price / Book Value Adj.	1,7				
EV /EBIT (95% EBIT)	8,0				
EV / Sales (95% Sales)	1,1				

El.En. Market Cap.	712,3 @ €8,89
Net financial position	110,6 @ 31/12/2024
Financial investments m/l term	7,6 @ 31/12/2024
Enterprise Value	594,1

Dec. 31st, 2024	Price on	Revenue	Var.%	EBIT	EBIT	MK.Cap.	EV	EV/Sales	EV/EBIT	P/Book
Medical/Aesthetic	M ar.24, 2025	Revenue	Rev.	LDII	%	ivik.cap.	LV	(*)	(*)	Value
InMode	\$19,02	\$395	-20%	\$113	29%	\$1.450	\$858	2,2	7,6	2,1
Beauty Health	\$1,36	\$334	-16%	\$(68)	-20%	\$168	\$367	1,1	n.a.	3,2
Venus (2)	\$3,07	\$49	-16%	\$(21)	-42%	\$2	\$36	0,5	n.a.	0,2
Sisram Medical	\$0,58	\$349	-3%	\$35	10%	\$273	\$248	0,7	7,1	0,6
Classys	€36,14	€ 165	29%	€ 83	50%	€ 2.365	€ 2.321	14,1	28,0	7,9
Industrial IPG Photonics Co.	\$66,50	\$977	-24%	\$(208)	-21%	\$2.880	\$2.010	2,1	n.a.	1,4
Han's Laser (2)	¥29,23	¥10.047	8%	¥146	1%	¥26.970	¥26.948	2,0	138,4	1,7
Bystronic	CHF 325	CHF 648	-30%	-CHF 84	-13%	CHF 594	CHF 172	0,3	n.a.	0,9
Amada	1.520 JPY	393.111 JPY	0%	45.935 JPY	12%	518.500 JPY	446.818 JPY	1,1	9,7	1,0
Yamazaki	326 JPY	3.036 JPY	21%	89 JPY	3%	1.490 JPY	2.547 JPY	0,8	28,5	1,1
HuaGong Tech (2)	¥42,33	¥8.967	25%	¥694	8%	¥42.563	¥44.283	3,7	48,0	4,3
El.En. (1)	€ 8,89	€ 566	-2%	€ 78	14%	€ 712	€ 594	1,1	8,0	1,7

⁽¹⁾ EV and multiplies as for previous slide

⁽²⁾ Financials @ 30.09.2024

^(*) Revenue, Ebit and earnings annualized







CONTACTS

El.En. S.P.A.

Enrico Romagnoli

Investor Relations Manager
tel. +39 055-8826807

E-mail: finance@elen.it

POLYTEMS HIR

Financial Communication, IR and Press Office

Bianca Fersini Mastelloni - b.fersini@polytemshir.it

Silvia Marongiu - s.marongiu@polytemshir.it

Tel. +39 06-69923324